Add Formweb to your mobile device
Search results for:
pegfilgrastim
pegfilgrastim
| Drug Name | Form | Strength | Notes |
|---|---|---|---|
| Neulasta | SOLUTION, SUBCUTANEOUS | 6 mg/0.6 mL | |
| Fulphila | SOLUTION, SUBCUTANEOUS | jmdb 6 mg/0.6 mL | |
| Fylnetra | SOLUTION, SUBCUTANEOUS | pbbk 6 mg/0.6 mL | |
| Nyvepria | SOLUTION, SUBCUTANEOUS | apgf 6 mg/0.6 mL | |
| Stimufend Prefilled Syringe | SOLUTION, SUBCUTANEOUS | fpgk 6 mg/0.6 mL | |
| Udenyca Autoinjector | SOLUTION, SUBCUTANEOUS | cbqv 6 mg/0.6 mL | |
| Udenyca Onbody | SOLUTION, SUBCUTANEOUS | cbqv 6 mg/0.6 mL | |
| Udenyca Prefilled Syringe | SOLUTION, SUBCUTANEOUS | cbqv 6 mg/0.6 mL | |
| Ziextenzo | SOLUTION, SUBCUTANEOUS | bmez 6 mg/0.6 mL | |
| Neulasta Onpro Kit | SOLUTION, SUBCUTANEOUS | 6 mg/0.6 mL |
Last updated: Jan. 9, 2024
- RCRA: Disposal
- RCRA: Management of Pharmaceutical Waste Policy
- Restricted Restricted Medication
This medication is Inpatient Non-formulary and Restricted to Outpatient Use. Inpatient use requires approval by a physician department leader (i.e. Medical Director or Chair, or hospital CMO) collaborating with a pharmacy leader.
See HERE for more information and workflow.
See HERE for additional pharmacy workflow details.